Development of reverse genetic systems and mouse model for SARS-CoV-2
$197,500R01FY2020AINIH
University Of Texas Med Br Galveston, Galveston TX
Investigators
Linked publications & trials
Paper 39616206Paper 38948778Paper 38422166Paper 38005825Paper 37503276Paper 37285402Paper 37252973Paper 36151059Paper 36138032Paper 36074821Paper 35937499Paper 35868235Paper 35533195Paper 35284912Paper 35263596Paper 35194609Paper 35140233Paper 35132410Paper 34845215Paper 34818667Paper 34494020Paper 34464596Paper 34192518Paper 34082438Paper 33851161Paper 33791696Paper 33767200Paper 33758836Paper 33691138Paper 33664494Paper 33652634Paper 33558724Paper 33532771Paper 33514944Paper 33494095Paper 33473190Paper 33473140Paper 33469576Paper 33442691Paper 33337934Paper 33232299Paper 33106671Paper 33060595Paper 32979938Paper 32938761Paper 32935091Paper 32908978Paper 32792628Paper 32747564Paper 32735900Paper 32669438Paper 32641828Paper 32607511Paper 32574959Paper 32511335Paper 32289263Paper 31694946Paper 31661051Paper 31462558
Abstract
ABSTRACT The recent epidemic of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused global public health emergency. Rapid response to disease control and countermeasure development is a public health priority. Reverse genetic systems and animal models are essential tools for studying viral replication, pathogenesis, vaccine development, and antiviral discovery. The goals of this supplement project are to (i) establish the reverse genetic systems and (ii) generate a mouse pathogenesis model for SARS-CoV-2.
View original record on NIH RePORTER →